Clinical Trial Update: EF-M2 (Immutalon) Multiple Ascending Dose Study in Moderate-to-Severe Rheumatoid Arthritis [Phase 1, Phase 2]

View source ↗

Summary

EF-M2 (Immutalon) multiple ascending dose study in moderate-to-severe rheumatoid arthritis has completed (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• EF-M2 (Immutalon) (EF-M2)

Snippet

Sponsor: S.LAB (SOLOWAYS) | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED